Cancer Target Group– molecular and fuctional analysis in lymphoid proliferative disorders

Our research focus on finding biological answers to clinically important questions involving improved diagnosis, stratification and treatment of patients with lymphoma. The main problem with successfully treating cancer lies in the heterogeneity of the malignancy, and tools that may capture that heterogeneity and provide evidence for variations in tumor-related signaling pathways and/or interaction with surrounding immune microenvironment is a holy grail. To advance the field, we collaborate closely with clinicians to perform advanced molecular investigations of patient material derived from within and outside clinical trials, including sequencing, spatial omics technologies, serum protein profiling and functional screening.